InspireMD, Ltd., a Tel Aviv, Israel company, has been granted CE Mark of approval by the European Union to market its innovative coronary stent MGuard™, a combination device thought to induce smooth and stable endothelial growth, reduce late thrombosis, and provide embolic protection during and post implantation.
More about the MGuard™:
The MGuard™ Coronary stent presents a novel combination of a coronary stent merged with an embolic protection device. The embolic protection device is comprised of an ultra-thin polymer mesh protective sleeve, wrapped around the stent. The protective sleeve is composed of a micron-level-fiber knitted mesh, engineered in an optimal geometric configuration and designed for utmost flexibility while retaining strength characteristics of the fiber material. The sleeve is designed to expand seamlessly when the stent is deployed, without affecting the structural integrity of the stent, and to prevent plaque detachment during and post procedure. The MGuard™ Coronary stent provides long acting embolic protection, without adding complexity in deliverability. The sleeve is designed to diffuse stent pressure on the vessel wall, thereby may reduce injury and lower the likelihood of restenosis.
Product page: The MGuard™ …
Press release: InspireMD’s MGuard™ Coronary Stent Receives CE Mark …